Navigating the CMS 14-Day Rule in Biomarker Testing

David L Rimm, MD, PhD
Professor of Pathology and Medicine (Oncology)
Yale University School of Medicine
New Haven, CT
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Director, Thoracic Oncology Research Program Associate Director for Translational
Research Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Related Articles
Building an Award-Winning Local Navigator Network
October 2019 Vol 10, No 10
An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network
The CAPE Initiative: Developing Meaningful Educational Materials to Elevate Quality of Life for Patients with Lung Cancer
July 2019 Vol 10, No 7
An Interview with Cheryl Bellomo, MSN, RN, OCN, ONN-CG, and Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T)
An Interview with Gregory C. Simon, JD, About the Biden Cancer Initiative’s Strategies to Improve Cancer Care
Kristin Siyahian
|
March 2019 Vol 10, No 3
Last modified: January 16, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code